Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Question

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Direct answer

    CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-as-q2-sales-hit-3d4915

    POLICY
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.
    CRSPVRTX
    Impact
    69
    SEP 9
    SIG
    85%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.
    → FDA pediatric label expansion broadens Casgevy addressable patient population, driving sequential revenue growth for CRSP and partner VRTX.
    Impact
    CRISPR Therapeutics saw commercial acceleration for Casgevy, with second-quarter revenue reaching $76 million, a 78% quarter-over-quarter increase. The therapy received FDA approval to expand its label to pediatric patients aged 2 and older, broadening the commercial pool for hemoglobinopathy treatments in partnership with Vertex Pharmaceuticals.
    Affected
    CRSPVRTX
    Transmission
    FDA pediatric label expansion broadens Casgevy addressable patient population, driving sequential revenue growth for CRSP and partner VRTX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial revenue growth from regulatory label expansionUp1-3mCasgevy Q2 sales grew 78% QoQ to $76M and FDA approved label expansion for ages 2+.
    VRTXshared commercialization economics on Casgevy rolloutUp1-3mVRTX is co-commercializing Casgevy with CRSP across blood disorder indications.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month